Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Quick Links Investor Presentation Responsibility News Portfolio Responsibility Report Annual Reports Leadership Governance SEC Filings Latest Press Releases April 11, 2024 Incyte to Report First Quarter Financial Results April 1, 2024 Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia March 29, 2024 Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) All press releases Latest Events Apr 30 2024 Apr 30 2024 Q1 2024 Incyte Corporation Earnings Conference Call Click here for Webcast Mar 11 2024 Mar 11 2024 Incyte Data Highlights from AAD 2024 Click here for Webcast All events
